News

A recent study reveals that anaphylaxis rates remain stable during the COVID-19 pandemic, despite reduced emergency visits.

A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for nAMD.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

In a recent review, experts answer frequent questions allergists have about conducting proximity challenges in patients with food allergy anxiety.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.

NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.

The asthma-related emergency department visits highlighted here, following the Canadian wildfires near Ontario, were attributed to smoke inhalation.

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.

New findings reveal that higher HbA1c levels worsen asthma control in children, linking metabolic dysfunction to increased asthma morbidity.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

These data suggest that heart health, as determined by the LC9 assessment, is positively correlated with pulmonary health.

Subgroup analysis findings highlight duvakitug’s efficacy and tolerability across different levels of inflammation in ulcerative colitis.

Digital inhalers enhance asthma control and reduce severe exacerbations, offering promising benefits with minimal harm for patients struggling with adherence.

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

A variety of influences and potential confounders exist to explain the increasing rates of impairment concordant with chronic obstructive pulmonary disease.

Virtual pulmonary rehabilitation enhances access and improves outcomes for COPD patients, demonstrating safety and effectiveness in individualized care.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

New research reveals Medicaid unwinding disrupts chronic medication access for young adults, risking health and treatment outcomes amid enrollment losses.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

A post hoc analysis of data from the PULSAR trial indicates that patients with aflibercept 8 mg achieved disease activity control early and in high proportion.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.